Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Eric Wong MD

Eric T. Wong MD

Associate Professor, Department of Neurology, Harvard Medical School; Co-Director, Brain Tumor Center, Beth Israel Deaconess Medical Center

Dr. Eric T. Wong received his medical training at Robert Wood Johnson Medical School in Piscataway, New Jersey, and completed his internship in internal medicine at New Jersey Medical School in Newark. He underwent residency training in neurology at the Washington University Medical Center in St. Louis, Missouri, and subsequently completed fellowships in neuro-oncology at Memorial Sloan-Kettering Cancer Center in New York and University of Texas MD Anderson Cancer Center in Houston.

 

Dr. Wong is co-director of the Brain Tumor Program and director of the Neuro-Oncology Unit at Beth Israel Deaconess Medical Center in Boston. His research interest is in biomarker discovery to enable neuro-oncologists and medical oncologists to better predict response to conventional cytotoxic chemotherapy and/or targeted therapies. He played a key role in the pivotal clinical trial and the FDA approval in 2011 of the NovoTTF-100A device, a novel treatment for recurrent glioblastoma. He has served on the editorial boards of the Journal of Clinical Oncology and Cancer Medicine. Dr. Wong is also the president of the Massachusetts Society of Clinical Oncologists and, in this capacity, he has fought on behalf of cancer patients for coverage of lifesaving treatments.